2024-04-02 06:01:11 ET
Summary
- Viking Therapeutics' share price has rapidly increased from recent weight loss drug excitement.
- The company’s value seems to be derived from its weight loss and NASH/MASH candidates.
- VK2735, the weight loss candidate, presents a potentially massively large opportunity, despite the crowded market.
- VK2809, the NASH/MASH candidate, now offers an attractive opportunity as a recently launched drug provides proof-of-concept for the space.
Introduction
Viking Therapeutics ( VKTX ) is a biotech focusing on bringing metabolic treatments to market. They seem to be largely focused in areas of broad interest, such as obesity (with their GLP-1/GIP agonist), and NASH (nonalcoholic steatohepatitis, with a TR-Beta agonist). Both have had some recent excitement, for example, Eli Lilly's ( LLY ) and Novo Nordisk's ( NVO ) successes with the ever-expanding obesity market (which may surpass a hefty ~$77B within the next decade). Madrigal Pharmaceuticals’ ( MDGL ) recent launch of Rezdiffra has also potentially opened up the NASH market, which may exceed ~$48B by 2035. These opportunities combined with some of VKTX's recent clinical success, can help explain the stock's rapid increase within the past month....
Read the full article on Seeking Alpha
For further details see:
Viking Therapeutics: Future Weight Loss Heavyweight?